Terms: = Brain cancer AND FGFR3, CD333, 2261, ENSG00000068078, P22607, JTK4, ACH, HSFGFR3EX, CEK2 AND Prognosis
9 results:
1. Clinical significance of molecular subgroups of polymorphous low-grade neuroepithelial tumor of the young (PLNTY): A small single institutional case series and integrated analysis.
Vuong HG; Alzayadneh E; Reith TP; Eschbacher KL
Pathol Res Pract; 2023 Dec; 252():154922. PubMed ID: 37984047
[TBL] [Abstract] [Full Text] [Related]
2. Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with fgfr3::TACC3 fusion.
Métais A; Tauziède-Espariat A; Garcia J; Appay R; Uro-Coste E; Meyronet D; Maurage CA; Vandenbos F; Rigau V; Chiforeanu DC; Pallud J; Senova S; Saffroy R; Colin C; Edjlali M; Varlet P; Figarella-Branger D;
Acta Neuropathol Commun; 2023 Jan; 11(1):14. PubMed ID: 36647073
[TBL] [Abstract] [Full Text] [Related]
3. Targeting gene fusions in glioma.
Kim PL
Curr Opin Neurol; 2021 Dec; 34(6):840-847. PubMed ID: 34766555
[TBL] [Abstract] [Full Text] [Related]
4. [Master regulators associated with poor prognosis in glioblastoma multiforme].
Kalya MP; Beisbarth T; Kel A
Biomed Khim; 2021 May; 67(3):201-212. PubMed ID: 34142527
[TBL] [Abstract] [Full Text] [Related]
5. Novel targetable FGFR2 and fgfr3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs.
Georgescu MM; Islam MZ; Li Y; Traylor J; Nanda A
Acta Neuropathol Commun; 2021 Apr; 9(1):69. PubMed ID: 33853673
[TBL] [Abstract] [Full Text] [Related]
6. Diffuse gliomas with fgfr3-TACC3 fusion have characteristic histopathological and molecular features.
Bielle F; Di Stefano AL; Meyronet D; Picca A; Villa C; Bernier M; Schmitt Y; Giry M; Rousseau A; Figarella-Branger D; Maurage CA; Uro-Coste E; Lasorella A; Iavarone A; Sanson M; Mokhtari K
Brain Pathol; 2018 Sep; 28(5):674-683. PubMed ID: 28976058
[TBL] [Abstract] [Full Text] [Related]
7. [Clinical analysis of paraneoplastic neurological syndrome associated with thymoma].
Liu HS; Ren HT; Zhou LX; Li SQ; Peng B; Cui LY; Guan HZ
Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(35):2770-2774. PubMed ID: 28954337
[No Abstract] [Full Text] [Related]
8. IGFBP2 expression predicts IDH-mutant glioma patient survival.
Huang LE; Cohen AL; Colman H; Jensen RL; Fults DW; Couldwell WT
Oncotarget; 2017 Jan; 8(1):191-202. PubMed ID: 27852048
[TBL] [Abstract] [Full Text] [Related]
9. Carboplatin as second line treatment for recurrent or progressive brain metastases from small cell lung cancer.
Groen HJ; Smit EF; Haaxma-Reiche H; Postmus PE
Eur J Cancer; 1993; 29A(12):1696-9. PubMed ID: 7691116
[TBL] [Abstract] [Full Text] [Related]
